A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 148
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : mCRC
Long Form : metastatic CRC
No. Year Title Co-occurring Abbreviation
2020 Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer. CRCs
2020 Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. CRC
2020 Pembrolizumab for the treatment of colorectal cancer. CRC, ICI, MSI, MSS
2020 Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. CRC, IPTW, MSI, OS, PFS
2020 Prognostic and therapeutic implications of NHERF1 expression and regulation in colorectal cancer. CRC, IGF1R, NHERF1, XIAP
2020 The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. CRC
2019 BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. CRC
2019 Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. CRC, MSI-H
2019 Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer. LNs
10  2019 Effect of systemic treatment on the micronuclei frequency in the peripheral blood of patients with metastatic colorectal cancer. CBMN assay, CRC, MN, PBLs
11  2019 Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). CRC, HORG, OS, PFS
12  2019 Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. CRC
13  2019 Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. anti-EGFR, CRC, HER2, MMR, MSI, RTK
14  2019 Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. CI, CRC, FDR, OR, SNPs, TET
15  2019 Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients. CRC, OR, OS, wtKRAS
16  2019 Nanotechnology-based siRNA delivery strategies for metastatic colorectal cancer therapy. CRC, PLGA, siRNA
17  2019 Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. CRC, dMMR, MSI, MSS, OS, PD-1
18  2019 PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis. CRC, PDX
19  2019 Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses. CRC, ILC, PBMCs
20  2019 Prognostic impact of ATM mutations in patients with metastatic colorectal cancer. CRC, OS
21  2019 Ramucirumab: the long and winding road toward being an option for mCRC treatment. CRC, FDA
22  2019 Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer. CRCs, ORR
23  2019 Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. AC, CRC, MTs, SRCC
24  2019 Synchronous vascular endothelial growth factor protein profiles in both tissue and serum identify metastasis and poor survival in colorectal cancer. CRC, PlGF, sVEGFRs, VEGFRs, VEGFs
25  2019 The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review. CRC, EGFR, MMR, MSI
26  2019 Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study. CRC, LT
27  2019 Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status. CRC, dMMR
28  2019 Tumor-associated redox state in metastatic colorectal cancer. CRC, EPR, LF, MMP, NO, SR
29  2018 Anti-angiogenic agents in second-line treatment for metastatic colorectal cancer: the optimization of pharmacological costs. CRC, PFS, RCTs
30  2018 Anti-Angiogenics: Their Value in Colorectal Cancer Therapy. CRC, VEGF
31  2018 Colorectal Cancer: Why Does Side Matter? CIMP, CRC, DFS, EGFR, LS, PTL, RS
32  2018 Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. anti-EGFR, CI, CMS, CRC, HR, IRI, OS, OX, PFS
33  2018 Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis. CRC
34  2018 Cost-effectiveness of new and emerging treatment options for the treatment of metastatic colorectal cancer. CRC
35  2018 Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. BRAFms, CRC
36  2018 Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. CRC
37  2018 Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a "me too" drug? CRC, FDA
38  2018 Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. QALYs
39  2018 Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. SA
40  2018 Molecular characterization and biomarker identification in colorectal cancer: Toward realization of the precision medicine dream. CRC
41  2018 Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. CHM, CRC
42  2018 Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer. CI, CRC, HR
43  2018 Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. BMI, BMI, CRC, ORR, OS, PFS
44  2018 Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. CRC, EGFRIs, HR, OS, PFS
45  2018 Prognostic Significance of Serum Lactic Acid, Lactate Dehydrogenase, and Albumin Levels in Patients with Metastatic Colorectal Cancer. ALB, LDH, non-mCRC, sLA
46  2018 The genemutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing. NGS, qPCR
47  2018 The predictive value of primary tumor location in patients with metastatic colorectal cancer: A systematic review. anti-EGFR, CRC
48  2018 The role of tumor angiogenesis as a therapeutic target in colorectal cancer. CRC
49  2018 Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. CAFs, CRC
50  2018 Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality. CRCs, HES, OS, TILs
51  2018 Vitamin D Supplementation and Survival in Metastatic Colorectal Cancer. CRC, OS, PFS
52  2017 A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. MTD
53  2017 An Expanding Role for Immunotherapy in Colorectal Cancer. CPIs, CRC, MSI-H
54  2017 Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. CRC
55  2017 Chromothripsis and progression-free survival in metastatic colorectal cancer. CRC, PFS
56  2017 Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report. CRC
57  2017 Differential expression of hENT1 and hENT2 in colon cancer cell lines. CRC, hENT
58  2017 Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer. CRC, miR-199b
59  2017 KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. BCC, CRC, ECOG
60  2017 Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. CRC, DCE, PFS
61  2017 Patient considerations in metastatic colorectal cancer - role of panitumumab. CRC, EGFR, mAbs
62  2017 Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study. CRC, CT, CTCs, OS, PFS
63  2017 Research progress on genetic heterogeneity between primary and paired metastatic colorectal cancer. CRC
64  2017 Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. CRC, dMMR, pMMR, RR
65  2017 Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. CRC, OS, PFS
66  2017 Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. AIs, CRC, VEGF
67  2017 The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. CRC, OS, TFS
68  2017 Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. CRC, ORR
69  2016 Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. BMI, CRC
70  2016 Circulating microRNAs as Prognostic and Predictive Biomarkers in Patients with Colorectal Cancer. CRC
71  2016 Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer. CRC
72  2016 Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients. CRC
73  2016 Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. CRC, CTCs, ISET, PFS, wtKRAS
74  2016 ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. CRC
75  2016 G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. CRC, KRAS, OS, PFS
76  2016 Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer. CRC
77  2016 KRAS mutation in lung metastases from colorectal cancer: prognostic implications. CRC, HR, LDFS, LM, OS, PFS, PTEN, WT
78  2016 KY1022, a small molecule destabilizing Ras via targeting the Wnt/beta-catenin pathway, inhibits development of metastatic colorectal cancer. CRC
79  2016 Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. CRCs, EGFR
80  2016 Metastatic Colorectal Cancer in Young Adults: A Study From the South Australian Population-Based Registry. CRC
81  2016 Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer. APC, CRC, MSP, oCRC, RASSF1A
82  2016 Options for Second-Line Treatment in Metastatic Colorectal Cancer. CRC, FDA
83  2016 RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy. CRC, OS
84  2016 Regorafenib in the treatment of colorectal cancer. CRC
85  2016 Role of targeted therapy in metastatic colorectal cancer. CRC, EGFR, VEGF
86  2016 Targeted Therapy of Colorectal Cancer. CRC, EGFR, VEGF
87  2016 The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. CRCs, MSS, PD, PD-L1
88  2016 Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. CRC, EGFR, mAbs, OS
89  2016 Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. CRC, EGFR, NSCLC
90  2016 Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. CRC, SNPs, topo-1
91  2016 Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. dMMR, MT, WT
92  2015 A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C. CRC, HDL-C, LDL-C, LHR, OS, PFS
93  2015 Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. CI, CRC, HR, OS, PFS, RR
94  2015 Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. CI, CRC, HR, OS, PFS, RR
95  2015 Anti-angiogenic agents in metastatic colorectal cancer. CRC
96  2015 Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study. CRC, FU, OS, PFS
97  2015 Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer. CRC, EGFR, KRAS, MET, NRAS
98  2015 Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. CRC, ORR
99  2015 Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. CRC, HR, IL, LDH, OS
100  2015 Mitochondrial microsatellite instability in patients with metastatic colorectal cancer. CRC, MSI, MSS, mtMSI, OS